Cargando…
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO‐3 randomized trial
OBJECTIVES: This study sought to investigate the clinical outcomes of patients with and without peripheral artery disease (PAD) in the BRAVO‐3 trial with respect to the effect of bivalirudin versus unfractionated heparin (UFH). BACKGROUND: PAD is found frequently in patients undergoing transcatheter...
Autores principales: | Zilberszac, Robert, Chandiramani, Rishi, Hengstenberg, Christian, Sartori, Samantha, Cao, Davide, Chandrasekhar, Jaya, Schafer, Ulrich, Tchetche, Didier, Violini, Roberto, Jeger, Raban, Van Belle, Eric, Boekstegers, Peter, Hambrecht, Rainer, Tron, Christophe, Dumenteil, Nicolas, Linke, Axel, ten Berg, Jurriën M., Deliargyris, Efthymios N., Anthopoulos, Prodromos, Mehran, Roxana, Dangas, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540270/ https://www.ncbi.nlm.nih.gov/pubmed/31808295 http://dx.doi.org/10.1002/ccd.28642 |
Ejemplares similares
-
Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017) -
Severe structural valve deterioration after TAVR with ACURATE Neo: report of two cases
por: Schaeffer, Thibault, et al.
Publicado: (2023) -
Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess?
por: Chandiramani, Rishi, et al.
Publicado: (2020) -
Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
por: Zeymer, Uwe, et al.
Publicado: (2014) -
Bravo!
Publicado: (1984)